# Creative Medical Technology Holdings, Inc.: Form 10-Q for the period ended Sep 30, 2019

- Company: [Creative Medical Technology Holdings, Inc.](/companies/celz.md) (CIK 1187953)
- Form: 10-Q
- Filed: 2019-11-14
- Accepted by EDGAR: Nov 14, 2019, 16:46 ET
- Period: 2019-09-30
- Accession: 0001104659-19-064296
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1187953/000110465919064296/tm1919487d1-10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1187953/000110465919064296/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-07-01 to 2019-09-30 | $57.5k | us-gaap:Revenues |
| Revenue | 9 months, 2019-01-01 to 2019-09-30 | $169.9k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2019-07-01 to 2019-09-30 | $8.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2019-01-01 to 2019-09-30 | $41.4k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2019-07-01 to 2019-09-30 | $49.5k | us-gaap:GrossProfit |
| Gross profit | 9 months, 2019-01-01 to 2019-09-30 | $128.5k | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-07-01 to 2019-09-30 | $0 | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2019-01-01 to 2019-09-30 | $0 | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2019-07-01 to 2019-09-30 | −$273.4k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2019-01-01 to 2019-09-30 | −$799.6k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-07-01 to 2019-09-30 | $529.2k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2019-01-01 to 2019-09-30 | $1.5m | us-gaap:InterestExpense |
| Income tax | 3 months, 2019-07-01 to 2019-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2019-01-01 to 2019-09-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-07-01 to 2019-09-30 | −$2.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2019-01-01 to 2019-09-30 | −$3.3m | us-gaap:NetIncomeLoss |
| Operating cash flow | 9 months, 2019-01-01 to 2019-09-30 | −$960.7k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Current assets | at 2019-09-30 | $182.7k | us-gaap:AssetsCurrent |
| Total assets | at 2019-09-30 | $330.4k | us-gaap:Assets |
| Current liabilities | at 2019-09-30 | $3.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2019-09-30 | $3.9m | us-gaap:Liabilities |
| Long-term debt | at 2019-09-30 | $1.5m | us-gaap:LongTermDebt |
| Shareholders' equity | at 2019-09-30 | −$3.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 16,037 characters.

*Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets and statements of operations. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2018, and our interim financial statements and accompanying notes to these financial statements included in this report. All amounts are in U.S. dollars.*

### Forward-Looking Statement Notice

This quarterly report on Form 10-Q contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our most recent annual report referenced below.

This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements.

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

### Overview

We are considered to be a commercial stage company, following the commencement of sales of stem cell disposable kits used in our Caverstem procedure to treat ED in the fourth quarter of 2017 and our FemCelz procedure for vaginal rejuvenation. Our fiscal year end is December 31st. We have acquired the licensing rights for our Amniostem amniotic-based stem cell, purchased the patent for our ED and lower back pain treatments, and filed patent applications for our neurological treatments.

During the first nine months of 2019, we issued $1,275,400 in convertible notes with net proceeds of $1,047,295 to accredited investors. In addition, we issued $300,000 in convertible notes in exchange for the extinguishment of 9,698,736 warrants.

During the nine-month period ending September 30, 2019, we incurred interest expense of $1,487,984 arising from the third-party notes of $1,532,614.

#### Plan of Operations

We commenced marketing disposable stem cell separation kits for the Caverstem® ED treatment in the fourth quarter of 2017. We commenced marketing disposable stem cell separation kits for the FemCelz™ procedure to treat female sexual disfunction in the fourth quarter of 2018. For the next 12 months our plan of operations is to market our disposable kits, publish the result of the combined UCLA/LABiomed clinical trial and post-marketing patient results and partner with leading researchers on investigator-initiated trials to advance our neurological programs. As of September 30, 2019, we had approximately $158,236 cash on hand. With an estimated monthly cash burn rate of approximately $100,000 based on historic trends and anticipated future revenues and expenses, management anticipates sufficient cash on hand and committed funds to meet operating expenses and costs of the current operations through at least December 2019. Historically, we have met our cash flow requirements through the sale of equity securities or borrowed funds. We intend to fund our business through sales of disposable kits along with continuing to seek investments to meet our cash flow requirements, including both operating expenses and the balance of funding required to fund our sales efforts and complete our ED clinical trial. The securities offered by us to potential investors have not been registered under the Securities Act of 1933, as amended (the “Act”), and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

### Results of Operations – For the Three-Month Period Ended September 30, 2019 and 2018

***Gross Revenue.*** We generated $57,500 gross revenue for the three-month period ended September 30, 2019, in comparison with $52,400 for the comparable quarter a year ago. The increase of $5,100 or 10% reflects the increased sales of the disposable kits for the Caverstem and FemCelz procedures.

***Cost of Goods Sold***. We generated $8,000 cost of goods sold for the three-month period ended September 30, 2019, in comparison with $36,395 for the comparable quarter a year ago. The decrease of $28,395 or 78% reflects the lower per unit cost of the Caverstem 2.0 and FemCelz disposable kits and fewer kits used in training.

***Gross Profit/(Loss)***. We generated $49,500 in gross profit for the three-month period ended September 30, 2019, in comparison with $16,005 for the comparable quarter a year ago. The increase of $33,495 or 209% is primarily driver by lower per unit costs of the disposable kits.

***General and Administrative Expenses.*** General and administrative expenses for the three-month period ended September 30, 2019, totaled $317,636, in comparison with $282,670, for the comparable quarter a year ago. The increase of $34,966, or 12% is primarily due to an increase of $26,718 in marketing expenses offset by decreased travel expenses associated with the commercialization of the Caverstem and FemCelz procedures.

Research and D***evelopment Expenses.*** Research and development expenses for the three-month period ended September 30, 2019, totaled $0 in comparison with $2,884, for the comparable quarter a year ago. The decrease of $2,884, or 100% is due to a reduction of $2,884 in laboratory expenses.

***Other Income / Expense.*** Other expense for the three-month period ended September 30, 2019, totaled $2,132,702 in comparison with other expense of $1,296,185, for the comparable quarter a year ago. The increase of $836,517, or 65% is primarily due to an increased loss in the change of the fair value of derivative liabilities of $695,264 and a $152,150 increase in interest expense associated with an increase in the debt balance.

***Net Loss.*** For the reasons stated above, our net loss for the three-month period ended September 30, 2019, totaled $2,406,124 in comparison to $1,571,020, for the comparable quarter a year ago.

### Results of Operations – For the Nine-month Period Ended September 30, 2019 and 2018

***Gross Revenue.*** We generated $169,900 gross revenue for the nine-month period ended September 30, 2019 in comparison with $66,800 for the comparable quarter a year ago. The increase of $103,100 or 154% reflects the increased sales of the disposable kits for the Caverstem and FemCelz procedures.

***Cost of Goods Sold***. We generated $41,439 cost of goods sold for the nine-month period ended September 30, 2019 in comparison with $41,323 for the comparable quarter a year ago. The increase of $116 or 0.3% reflects the increased sales of the disposable kits for the Caverstem and FemCelz procedures offset by lower per unit costs of the disposable kits.

***Gross Profit/(Loss)***. We generated $128,461 in gross profit for the nine-month period ended September 30, 2019 in comparison with $25,477 for the comparable quarter a year ago. The increase of $102,984 or 404% reflects the increased sales of the disposable kits for the Caverstem and FemCelz procedures offset by lower per unit costs of the disposable kits.

***General and Administrative Expenses.*** General and administrative expenses for the nine-month period ended September 30, 2019, totaled $912,182, in comparison with $793,216, for the comparable period a year ago. The increase of $118,966, or 15% is primarily due to a $79,900 increase in marketing and a $60,000 increase in management fees offset by a $40,500 decrease in travel expenses.

***Research and Development Expenses.*** Research and development expenses for the nine-month period ended September 30, 2019, totaled $0 in comparison with $10,284, for the comparable period a year ago. The decrease of $10,284, or 100% is due to the completion of the pre-clinical research of the Amniostem®.

***Other Income / Expense.*** Other expense for the nine-month period ended September 30, 2019, totaled $2,492,144 in comparison with other expense of $14,796,123, for the comparable period a year ago. The decrease of $12,303,979, or 83% is primarily due to a reduction of $13,653,662 associated with the change in the fair value of derivative liabilities, offset by an increase of $506,643 in interest expense associated with a higher debt balance in comparison to comparable period a year ago.

***Net Loss.*** For the reasons stated above, our net loss for the nine-month period ended September 30, 2019 totaled $3,291,723 in comparison to $15,590,004, for the comparable period a year ago.

### Liquidity and Capital Resources

Our principal source of liquidity has been funds received from the sale of our common stock and issuance of notes including convertible notes. Our experience to-date indicates the lenders are most likely to convert the debt into equity prior to or in lieu of full payment at maturity. Going forward, our short-term funding needs are expected to be satisfied by funds to be loaned to us by third parties and revenues generated from our Caverstem ED and FemCelz vaginal rejuvination procedures. Our long-term liquidity needs are expected to be satisfied from future offerings of our equity securities. It is possible that CMH may provide future financing for us. We do not have any arrangements, agreements, or sources for long-term funding.

Our only commitments for expenditures relate to general and administrative costs, including reimbursements to our parent company for services performed by their executive officers on our behalf. During the next 12 months we also anticipate incurring expenses related to marketing activities for our ED and vaginal rejuvenation treatments.

For the next 12 months our plan of operations is to market our disposable kits, publish the results of the combined UCLA/LABiomed clinical trial and post-marketing patient results and partner with leading researchers on investigator-initiated trials to advance our neurological programs. We believe that our current cash on hand would meet our cash flow requirements for only a few more months. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

Our financial statements included with this report have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred substantial expenses and generated minimal revenues from operations during the periods covered by these financial statements. These factors raise substantial doubt about our ability to continue as a going concern. There is no assurance that we will be successful in meeting the continuing financial obligations of the company. Our financial statements do not include any adjustments that might result from the outcome of these uncertainties.

### Cash Flows

***Net Cash used in Operating Activities.*** We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was $960,661 for the nine-month period ended September 30, 2019 in comparison to $756,639 for the comparable period a year ago, an increase of $204,022 or 27%. The increase in cash used in operations was primarily related to increases in marketing expenses associated with commercialization of the Caverstem and FemCelz procedures combined with increased public company and shareholder-related expenses offset by expenditure reductions in travel and outside consultants

***Net Cash used in Investing Activities.*** There was no cash used in investing activities in the nine-month periods ended September 30, 2019 and September 30, 2018 respectively.

***Net Cash From Financing Activities.*** In the nine-month period ended September 30, 2019, we raised $1,047,295 through the issuance of convertible debt, expended $194,111 to retire convertible debt and paid $38,343 in prepayment premiums on the retired convertible notes. In the nine-month period ended September 30, 2018, we raised $1,378,072 through the issuance of convertible debt, expended $405,294 to retire convertible debt, and paid $57,004 in prepayment premiums on the retired convertible notes. The $100,933 or 11% decrease in cash flows from financing activities were primarily related to timing of our financing activities.

### Basis of Presentation / Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2019, the Company had $158,236 of available cash and a working capital deficit of $3,710,628. For the nine-month period ended September 30, 2019, the Company had $169,900 in revenue, $799,579 in operating loss and used net cash for operating activities of $960,661. These factors, among others, indicate that the Company may be unable to continue as a going concern for the next twelve months. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing as may be required, and ultimately to attain sufficient cash flow from operations to meet its obligations on a timely basis. Management is in the process of negotiating various financing plans including access to ongoing credit facilities and possible sale of capital stock either in private or in public offerings and believes these steps may generate sufficient cash flow for the Company to continue as a going concern. If the Company is unsuccessful in these efforts, it may be required to substantially curtail or terminate its operations.

### Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity capital expenditures or capital resources.

## Controls and procedures

As filed, 1,418 characters.

### Evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13(a)-15(e) of the Securities Exchange Act of 1934, as amended (the “**Exchange Act”**)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

### Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed Nov 14, 2019.
Source: SEC EDGAR, the filing index for accession 0001104659-19-064296. Last ingested by Listed: Nov 14, 2026, 19:08 ET. No prices; not investment advice.
